169 related articles for article (PubMed ID: 36580755)
41. Sentinel lymph node intraoperative analysis in endometrial cancer.
Bellaminutti S; Bonollo M; Gasparri ML; Clivio L; Migliora P; Mazzucchelli L; Papadia A
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3199-3205. PubMed ID: 32815026
[TBL] [Abstract][Full Text] [Related]
42. The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
Touhami O; Grégoire J; Renaud MC; Sebastianelli A; Grondin K; Plante M
Gynecol Oncol; 2018 Mar; 148(3):485-490. PubMed ID: 29290489
[TBL] [Abstract][Full Text] [Related]
43. Impact of comorbidities and extent of lymphadenectomy on quality of life in endometrial cancer patients treated with minimally invasive surgery in the era of sentinel lymph nodes.
Dinoi G; Multinu F; Yost K; AlHilli M; Larish A; Langstraat C; Kumar A; Weaver AL; McGree M; Cheville A; Dowdy S; Mariani A; Glaser G
Int J Gynecol Cancer; 2023 Aug; 33(8):1227-1236. PubMed ID: 37419517
[TBL] [Abstract][Full Text] [Related]
44. A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial).
Grassi T; Mariani A; Cibula D; Soliman PT; Suman VJ; Weaver AL; Pedra Nobre S; Weigelt B; Glaser GE; Cappuccio S; Abu-Rustum NR
Int J Gynecol Cancer; 2020 Oct; 30(10):1627-1632. PubMed ID: 32699021
[TBL] [Abstract][Full Text] [Related]
45. Surgical and oncological outcomes of sentinel lymph node sampling in elderly patients with intermediate to high-risk endometrial carcinoma.
Matanes E; Eisenberg N; Mitric C; Yasmeen A; Ismail S; Raban O; Cantor T; Knigin D; Lau S; Salvador S; Gotlieb W; Kogan L
Int J Gynecol Cancer; 2022 Jul; 32(7):875-881. PubMed ID: 35680137
[TBL] [Abstract][Full Text] [Related]
46. Sentinel lymph node mapping in endometrial cancer: performance of hysteroscopic injection of tracers.
Martinelli F; Ditto A; Bogani G; Leone Roberti Maggiore U; Signorelli M; Chiappa V; Raspagliesi F
Int J Gynecol Cancer; 2020 Mar; 30(3):332-338. PubMed ID: 31911536
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer.
Kim MK; So KA; Chun YK; Kim YH; Lim KT; Lee KH; Kim TJ
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):724-728. PubMed ID: 37679002
[TBL] [Abstract][Full Text] [Related]
48. Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon?
Mueller JJ; Rios-Doria E; Park KJ; Broach VA; Alektiar KM; Jewell EL; Zivanovic O; Sonoda Y; Abu-Rustum NR; Leitao MM; Gardner GJ
Gynecol Oncol; 2023 Jan; 168():1-7. PubMed ID: 36334496
[TBL] [Abstract][Full Text] [Related]
49. Retrospective validation of the laparoscopic ICG SLN mapping in patients with grade 3 endometrial cancer.
Papadia A; Gasparri ML; Radan AP; Stämpfli CAL; Rau TT; Mueller MD
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1385-1393. PubMed ID: 29691646
[TBL] [Abstract][Full Text] [Related]
50. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics.
Marchocki Z; Cusimano MC; Clarfield L; Kim SR; Fazelzad R; Espin-Garcia O; Bouchard-Fortier G; Rossi EC; Stewart KI; Soliman PT; How JA; Gotlieb WH; Holloway RW; Ianieri MM; Cabrera S; Lim YK; Ferguson SE
Am J Obstet Gynecol; 2021 Oct; 225(4):367.e1-367.e39. PubMed ID: 34058168
[TBL] [Abstract][Full Text] [Related]
51. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
Pasanen A; Loukovaara M; Bützow R
Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
[TBL] [Abstract][Full Text] [Related]
52. Mismatch repair status in high-grade endometrial carcinomas of endometrioid and non-endometrioid type.
Doulgeraki T; Vagios S; Kavoura E; Yiannou P; Messini I; Nonni A; Papadimitriou C; Vlachos A; Pavlakis K
J BUON; 2019; 24(5):2020-2027. PubMed ID: 31786870
[TBL] [Abstract][Full Text] [Related]
53. Lymphovascular space invasion and positive pelvic lymph nodes are independent risk factors for para-aortic nodal metastasis in endometrioid endometrial cancer.
Solmaz U; Mat E; Dereli ML; Turan V; Tosun G; Dogan A; Sanci M; Ozdemir IA; Pala EE
Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():63-7. PubMed ID: 25638600
[TBL] [Abstract][Full Text] [Related]
54. Lymph node evaluation in high-risk early stage endometrial cancer: A multi-institutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy.
Buda A; Gasparri ML; Puppo A; Mereu L; De Ponti E; Di Martino G; Novelli A; Tateo S; Muller M; Landoni F; Papadia A
Gynecol Oncol; 2018 Aug; 150(2):261-266. PubMed ID: 29887483
[TBL] [Abstract][Full Text] [Related]
55. A prospective evaluation of the sentinel node mapping algorithm in endometrial cancer and correlation of its performance against endometrial cancer risk subtypes.
Rajanbabu A; Agarwal R
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():77-80. PubMed ID: 29554604
[TBL] [Abstract][Full Text] [Related]
56. Comparison of oncological outcomes between sentinel lymph node biopsy and complete lymphadenectomy for endometrial cancer.
Makroum AA; Lee YJ; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
J Obstet Gynaecol Res; 2023 Aug; 49(8):2118-2125. PubMed ID: 37286510
[TBL] [Abstract][Full Text] [Related]
57. Prospective study of sentinel lymph node mapping for endometrial cancer.
Togami S; Kawamura T; Fukuda M; Yanazume S; Kamio M; Kobayashi H
Int J Gynaecol Obstet; 2018 Dec; 143(3):313-318. PubMed ID: 30125949
[TBL] [Abstract][Full Text] [Related]
58. Sentinel lymph node sampling versus full lymphadenectomy in endometrial cancer: a SEER database analysis.
Nahshon C; Kadan Y; Lavie O; Ostrovsky L; Segev Y
Int J Gynecol Cancer; 2023 Oct; 33(10):1557-1563. PubMed ID: 37487660
[TBL] [Abstract][Full Text] [Related]
59. Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial).
Baiocchi G; Andrade CEMC; Ribeiro R; Moretti-Marques R; Tsunoda AT; Alvarenga-Bezerra V; Lopes A; Costa RLR; Kumagai LY; Badiglian-Filho L; Faloppa CC; Mantoan H; De Brot L; Dos Reis R; Goncalves BT
Int J Gynecol Cancer; 2022 May; 32(5):676-679. PubMed ID: 35236752
[TBL] [Abstract][Full Text] [Related]
60. Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer.
Pelletier MP; Trinh VQ; Stephenson P; Mes-Masson AM; Samouelian V; Provencher DM; Rahimi K
Hum Pathol; 2017 Apr; 62():33-39. PubMed ID: 27864117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
